Literature DB >> 18595130

Adipokines and ghrelin in gastric cancer cachexia.

Mustafa Kerem1, Zafer Ferahkose, Utku Tonguc Yilmaz, Hatice Pasaoglu, Ebru Ofluoglu, Abdulkadir Bedirli, Bulent Salman, Tevfik Tolga Sahin, Murat Akin.   

Abstract

AIM: To investigate the roles of the adipocytokines, ghrelin and leptin in gastric cancer cachexia.
METHODS: Resistin, ghrelin, leptin, adiponectin, insulin and insulin-like growth factor (IGF-I), were measured in 30 healthy subjects, and 60 gastric cancer patients of which 30 suffered from cancer-induced cachexia and 30 served as a control group. The relationships between hormones, body mass index (BMI) loss ratio, age, gender, and Glasgow Prognostic Score (GPS) were investigated.
RESULTS: Cachexia patients had higher tumor stage and GPS when compared with non-cachexia patients (P < 0.05). Ghrelin, resistin, leptin, adiponectin and IGF-I, showed a significant correlation with BMI loss ratio and GPS (P < 0.05). A strong correlation was seen between GPS and BMI loss (R = -0.570, P < 0.0001). Multivariate analysis indicated that BMI loss was significantly independent as a predictor of ghrelin, resistin, leptin and IGF-I (P < 0.05). Existence of an important significant relationship between resistin and insulin resistance was also noted.
CONCLUSION: These results showed that serum ghrelin, leptin, adiponectin, and IGF-I play important roles in cachexia-related gastric cancers. No relationship was found between resistin and cancer cachexia. Also, because of the correlation between these parameters and GPS, these parameters might be used as a predictor factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595130      PMCID: PMC2719226          DOI: 10.3748/wjg.14.3633

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects.

Authors:  May Faraj; Peter J Havel; Steve Phélis; David Blank; Allan D Sniderman; Katherine Cianflone
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

Review 2.  Cachexia in cancer patients.

Authors:  Michael J Tisdale
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

3.  Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure.

Authors:  T Yoshikawa; Y Noguchi; C Doi; T Makino; K Nomura
Journal:  Nutrition       Date:  2001 Jul-Aug       Impact factor: 4.008

4.  Leptin and resistin: master enemy adipokines unified in brain to control glucose homeostasis.

Authors:  Remy Burcelin
Journal:  Endocrinology       Date:  2008-02       Impact factor: 4.736

5.  Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer.

Authors:  D R Brown; D E Berkowitz; M J Breslow
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

6.  Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors.

Authors:  N Nagaya; M Uematsu; M Kojima; Y Date; M Nakazato; H Okumura; H Hosoda; W Shimizu; M Yamagishi; H Oya; H Koh; C Yutani; K Kangawa
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

7.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

8.  Circulating concentrations of "free" leptin in relation to fat mass and appetite in gastrointestinal cancer patients.

Authors:  A Michael Wallace; Anne Kelly; Naveed Sattar; Colin S S McArdle; Donald C McMillan
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

9.  Increased plasma ghrelin level in lung cancer cachexia.

Authors:  Yoshito Shimizu; Noritoshi Nagaya; Takeshi Isobe; Michinori Imazu; Hiroyuki Okumura; Hiroshi Hosoda; Masayasu Kojima; Kenji Kangawa; Nobuoki Kohno
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

10.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; W J Angerson; D J Dunlop
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  30 in total

1.  Plasma desacyl ghrelin-to-acyl ghrelin ratio is a predictor of postoperative complications and prognosis after pancreaticoduodenectomy.

Authors:  Takahiro Nishida; Hironobu Tsubouchi; Takeomi Hamada; Naoya Imamura; Masahide Hiyoshi; Koichi Yano; Kenji Kangawa; Masamitsu Nakazato; Atsushi Nanashima
Journal:  Oncol Lett       Date:  2019-09-06       Impact factor: 2.967

Review 2.  Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.

Authors:  Benjamin H L Tan; James A Ross; Stein Kaasa; Frank Skorpen; Kenneth C H Fearon
Journal:  J Genet       Date:  2011-04       Impact factor: 1.166

Review 3.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

4.  Inflammatory cytokines, appetite-regulating hormones, and energy metabolism in patients with gastrointestinal cancer.

Authors:  Ayaka Shinsyu; Shigeki Bamba; Mika Kurihara; Hiroshi Matsumoto; Ayano Sonoda; Osamu Inatomi; Akira Andoh; Katsushi Takebayashi; Masatsugu Kojima; Hiroya Iida; Masaji Tani; Masaya Sasaki
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

Review 5.  Cancer cachexia: understanding the molecular basis.

Authors:  Josep M Argilés; Sílvia Busquets; Britta Stemmler; Francisco J López-Soriano
Journal:  Nat Rev Cancer       Date:  2014-10-09       Impact factor: 60.716

Review 6.  Genetic basis of interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies.

Authors:  N Johns; B H Tan; M MacMillan; T S Solheim; J A Ross; V E Baracos; S Damaraju; K C H Fearon
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

7.  Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.

Authors:  Kazuki Abe; Kaito Shibata; Takafumi Naito; Atsushi Otsuka; Masato Karayama; Masato Maekawa; Hideaki Miyake; Takafumi Suda; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2021-08-19       Impact factor: 2.953

8.  Adipocytokines and squamous cell carcinoma of the esophagus.

Authors:  Takako Eguchi Nakajima; Yasuhide Yamada; Tetsutaro Hamano; Koh Furuta; Ichiro Oda; Hoichi Kato; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

9.  Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer.

Authors:  Takako Eguchi Nakajima; Yasuhide Yamada; Tetsutaro Hamano; Koh Furuta; Takuji Gotoda; Hitoshi Katai; Ken Kato; Tetsuya Hamaguchi; Yasuhiro Shimada
Journal:  J Gastroenterol       Date:  2009-05-09       Impact factor: 7.527

10.  The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.

Authors:  Paraskevi Boura; Dimitra Grapsa; Stylianos Loukides; Maria Angelidou; Konstantina Tsakanika; Nikolaos Syrigos; Ioannis Gkiozos
Journal:  Lung Cancer Manag       Date:  2017-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.